Navigation Links
Positron emission tomography superior to standard evaluation tools in measuring treatment response
Date:1/31/2008

Positron Emission Tomography (PET) was much more sensitive and more accurate than conventional imaging methods in detecting response to treatment in sarcoma patients, according to a UCLA study that is among the first to directly compare PET to CT scanning.

The study has important implications for patients. If conventional imaging fails to detect treatment response, oncologists may discontinue therapies that in fact are working and study participants may be dismissed from clinical trials that are actually helping them. Conversely, if a patient is not responding, using PET scanning to evaluate response could help prevent them from undergoing toxic therapies that arent working.

The study, conducted by a multidiscplinary team of scientists at UCLAs Jonsson Cancer Center, appears in the Feb. 1, 2008 issue of Clinical Cancer Research. Researchers found that standard size-based evaluation methods only identified 20 percent of responders, while PET was able to identify responders 100 percent of the time.

Current practice evaluates response to treatment using RECIST, or Response Evaluation Criteria in Solid Tumors. Patients are scanned using CT or MRI before and after treatment and the scans are then compared to determine if the tumor has decreased in size. If there is no change, the disease is considered stable. A partial response is tumor shrinkage of more than 30 percent, while a total response is tumor elimination.

We knew from our considerable experience with neoadjuvant therapy (treatment before surgery) in sarcoma patients, that measuring tumor size correlated poorly with response, said Dr. Fritz Eilber, an assistant professor of surgery, director of the Sarcoma Program at UCLAs Jonsson Cancer Center and senior author of the study. We have removed many tumors that have not changed in size with treatment or have even grown, but are completely dead on pathologic analysis. Just because the tumor doesnt shrink doesnt mean the t
'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Groundbreaking Canada-US study proves link between emissions and mercury pollution in fish
2. CO2 emissions could violate EPA ocean-quality standards within decades
3. Groundbreaking Canada-US study proves link between emissions and mercury pollution in fish
4. RIT to study air pollution and greenhouse gas emissions in the Great Lakes region
5. Decline in uptake of carbon emissions confirmed
6. US faces burning emissions issue
7. Biodiesel could reduce greenhouse gas emissions
8. First-ever study to link increased mortality specifically to carbon dioxide emissions
9. Washington University, 2 industries, team to clean up mercury emissions
10. Mayo Clinic study: Ossurs collars superior in immobilization and reduction of pressure
11. Minimum information standards -- all for 1 and 1 for all
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics ... of human interface solutions, today announced collaboration with ... on Windows 10. Microsoft leveraged Synaptics, deep expertise ... operating system. Through stringent testing, ... fully certified with Microsoft,s Precision TouchPad (PTP) specification ...
(Date:8/4/2015)... AMRI ) today reported financial and operating results for the ... Second quarter contract revenue of $ 85.2 ... contract margins of 26 % , Second ... EPS from royalties in the current quarter , ... very pleased to present another strong financial quarter, with all our ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... PHILADELPHIA (July 30, 2012) When the longest cells in the ... repair is no easy task. This is in part because ... to one meter in adult humans which is a ... in order to reach the "command center" of the cell,s ...
... 2012) -- A rat may never be man,s best ... sponsored by scientists with the U.S. Army Research Laboratory, ... Counter Explosives Hazards Center, will determine if and how ... In July, Barron Associates Inc., Charlottesville, Va. was ...
... Xian Chang Li, MD, PhD, Brigham and Women,s Hospital (BWH) ... of lymphocytes, called CD4+ T cells, mature into various subsets ... that a particular cell surface molecule, known as OX40, is ... copious amounts of interleukin-9 (IL-9) (and therefore called TH9 cells) ...
Cached Biology News:Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3RATS research may teach rodents to detect explosives 2Cell receptor has proclivity for T helper 9 cells, airway inflammation 2
(Date:8/26/2015)... , August 26, 2015 Israel Proves ... DiaCardio wins 1 st place  Wayerz comes in ... Israel by venture capital fund JVP, with ... the US, China , Israel ... .  Impressive achievement for the Israeli representatives in ...
(Date:8/26/2015)... Boston, MA (PRWEB) , ... August 26, 2015 , ... ... venue for Boston adult stem cell technology start-up company Asymmetrex to share ... widely the capabilities of a new biomarker for counting adult tissue stem cells. , ...
(Date:8/25/2015)... Calif. (PRWEB) , ... August 25, 2015 , ... One ... Valley -based Resilinc Corp., Bindiya Vakil, has been on a mission for ... the impact on global supply chain operations - from the two massive explosions that ...
(Date:8/25/2015)... PRUSSIA, Pa. , Aug. 25, 2015   ... has been enrolled in its Phase II/III clinical study ... company,s recombinant fusion protein linking coagulation factor VIIa with ... hemophilia A or B who have developed an inhibitor ... study will enroll approximately 54 male patients, the first ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 2CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 3CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors 4
... Cardium Therapeutics,(NYSE: CXM ) today reported ... of Medicine showing the long-term outcome of a method ... disorder of the immune system.,The infant children studied had ... arises in infants with a genetic defect that,leaves them ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Secondary Endpoints -- CAPACITY 1 Misses Primary Endpoint, Provides ... MAA -BRISBANE, Calif., Feb. 3 InterMune, Inc. (Nasdaq: ... two Phase 3 CAPACITY studies evaluating pirfenidone in patients ... of change in percent predicted Forced Vital Capacity (FVC) ...
Cached Biology Technology:Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 2Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 3Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 4Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of Medicine 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 2InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 3InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 4InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 5InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 6InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 7InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 8InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 9InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 10InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF 11
... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
Request Info...
supplied with 10x reaction buffer...
... ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP ... of HK will phosphorylate 1 ... min at 25C at pH ... will oxidize 1 mol of ...
Biology Products: